Published in Curr Drug Deliv on May 01, 2011
Electroporation improves the efficacy of DNA vaccines in large animals. Vaccine (2002) 1.34
Rapid and versatile construction of diverse and functional nanostructures derived from a polyphosphoester-based biomimetic block copolymer system. J Am Chem Soc (2012) 1.26
Non-viral nucleic acid delivery: key challenges and future directions. Curr Drug Deliv (2011) 1.25
Increased gene expression and inflammatory cell infiltration caused by electroporation are both important for improving the efficacy of DNA vaccines. J Biotechnol (2004) 1.16
Endosomal escape and siRNA delivery with cationic shell crosslinked knedel-like nanoparticles with tunable buffering capacities. Biomaterials (2012) 1.02
Needle-free topical electroporation improves gene expression from plasmids administered in porcine skin. Mol Ther (2003) 0.97
Hierarchically assembled theranostic nanostructures for siRNA delivery and imaging applications. J Am Chem Soc (2012) 0.94
Degradable cationic shell cross-linked knedel-like nanoparticles: synthesis, degradation, nucleic acid binding, and in vitro evaluation. Biomacromolecules (2013) 0.93
Poly(ethylene oxide)-block-polyphosphoester-graft-paclitaxel conjugates with acid-labile linkages as a pH-sensitive and functional nanoscopic platform for paclitaxel delivery. Adv Healthc Mater (2013) 0.90
Topical non-invasive gene delivery using gemini nanoparticles in interferon-gamma-deficient mice. Eur J Pharm Biopharm (2007) 0.89
Improving paclitaxel delivery: in vitro and in vivo characterization of PEGylated polyphosphoester-based nanocarriers. J Am Chem Soc (2015) 0.88
In vivo cutaneous interferon-gamma gene delivery using novel dicationic (gemini) surfactant-plasmid complexes. J Gene Med (2005) 0.88
Advancing nonviral gene delivery: lipid- and surfactant-based nanoparticle design strategies. Nanomedicine (Lond) (2010) 0.87
Topical delivery of plasmid DNA using biphasic lipid vesicles (Biphasix). J Pharm Pharmacol (2002) 0.86
Shell crosslinked knedel-like nanoparticles for delivery of cisplatin: effects of crosslinking. Nanoscale (2013) 0.85
Thermodynamic and aggregation properties of aza- and imino-substituted gemini surfactants designed for gene delivery. Phys Chem Chem Phys (2006) 0.85
Characterization of polyion complex micelles designed to address the challenges of oligonucleotide delivery. Pharm Res (2008) 0.84
In vitro efficacy of paclitaxel-loaded dual-responsive shell cross-linked polymer nanoparticles having orthogonally degradable disulfide cross-linked corona and polyester core domains. Mol Pharm (2013) 0.84
Aminated linear and star-shape poly(glycerol methacrylate)s: synthesis and self-assembling properties. Biomacromolecules (2010) 0.83
Gemini surfactants: a new family of building blocks for non-viral gene delivery systems. Curr Gene Ther (2008) 0.83
Enhanced gene expression in epithelial cells transfected with amino acid-substituted gemini nanoparticles. Eur J Pharm Biopharm (2010) 0.82
siRNA nanocarriers based on methacrylic acid copolymers. J Control Release (2010) 0.82
Structural and transfection properties of amine-substituted gemini surfactant-based nanoparticles. J Gene Med (2007) 0.82
Amino acid-substituted gemini surfactant-based nanoparticles as safe and versatile gene delivery agents. Curr Drug Deliv (2011) 0.82
Transdermal delivery of insulin from a novel biphasic lipid system in diabetic rats. Diabetes Technol Ther (2002) 0.82
Challenges in neuroprotective nanomedicine development: progress towards noninvasive gene therapy of glaucoma. Nanomedicine (Lond) (2012) 0.81
Pharmaceutical characterization of solid and dispersed carbon nanotubes as nanoexcipients. Int J Nanomedicine (2012) 0.81
The haemopoietic growth factor, Flt3L, alters the immune response induced by transcutaneous immunization. Immunology (2002) 0.80
Investigation of complexes formed by interaction of cationic gemini surfactants with deoxyribonucleic acid. Phys Chem Chem Phys (2007) 0.80
Effect of chemical permeation enhancers on stratum corneum barrier lipid organizational structure and interferon alpha permeability. Mol Pharm (2013) 0.79
Mucosal delivery of bacterial antigens and CpG oligonucleotides formulated in biphasic lipid vesicles in pigs. AAPS J (2005) 0.79
Biphasic lipid vesicles (Biphasix) enhance the adjuvanticity of CpG oligonucleotides following systemic and mucosal administration. Curr Drug Deliv (2004) 0.78
Non-invasive immunization on the skin using DNA vaccine. Curr Drug Deliv (2006) 0.78
Synthesis, characterization, and use of asymmetric pyrenyl-gemini surfactants as emissive components in DNA-lipoplex systems. Langmuir (2007) 0.77
New technology and clinical applications of nanomedicine: highlights of the second annual meeting of the American Academy of Nanomedicine (Part I). Nanomedicine (2006) 0.77
Needle-free gene delivery through the skin: an overview of recent strategies. Curr Pharm Des (2013) 0.76
Drug delivery through the skin: molecular simulations of barrier lipids to design more effective noninvasive dermal and transdermal delivery systems for small molecules, biologics, and cosmetics. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2011) 0.76
Self assembling properties of aminated poly(glycerol methacrylate)s. J Control Release (2011) 0.76
Protection of Neonatal Broiler Chickens Following in ovo Delivery of Oligodeoxynucleotides Containing CpG Motifs (CpG-ODN) Formulated with Carbon Nanotubes or Liposomes. Avian Dis (2015) 0.76
Enhancement of immunoprotective effect of CpG-ODN by formulation with polyphosphazenes against E. coli septicemia in neonatal chickens. Curr Drug Deliv (2009) 0.76
In vivo sustained dermal delivery and pharmacokinetics of interferon alpha in biphasic vesicles after topical application. Eur J Pharm Biopharm (2013) 0.75
Correction to "Improving Paclitaxel Delivery: In Vitro and In Vivo Characterization of PEGylated Polyphosphoester-Based Nanocarriers". J Am Chem Soc (2015) 0.75
The 4th Annual Meeting of the American Society for Nanomedicine. J Neuroimmune Pharmacol (2014) 0.75
Evidence for lymphatic transport of insulin by topically applied biphasic vesicles. J Pharm Pharmacol (2003) 0.75
Biphasic lipid vesicles as a subcutaneous delivery system for protein antigens and CpG oligonucleotides. Curr Drug Deliv (2006) 0.75
Synthesis and solution properties of gemini surfactants containing oleyl chains. Phys Chem Chem Phys (2005) 0.75